



ASX ANNOUNCEMENT

1 FEBRUARY 2022

## **CHIMERIC SIGNS SPONSORED RESEARCH AGREEMENT WITH UNIVERSITY OF PENNSYLVANIA**

- Chimeric has executed a three-year Sponsored Research Agreement with the University of Pennsylvania, for research to be conducted in the laboratory of Xianxin Hua, MD, PhD
- The research will focus on furthering the development and understanding of CHM 2101 and on identifying CDH17 directed follow on candidates
- Chimeric continues to make excellent progress towards a phase 1 clinical trial for CHM 2101 in neuroendocrine tumours and gastrointestinal adenocarcinomas

Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announce that it has signed a Sponsored Research Agreement with the University of Pennsylvania ("Penn") to support the continued research and development of CHM 2101, a novel 3<sup>rd</sup> generation CDH17 CAR T cell therapy.

The research will be led by one of the inventors of CHM 2101, Xianxin Hua, MD, PhD. Dr Hua is a professor of Cancer Biology in Penn's Perelman School of Medicine, and an investigator at the Abramson Family Cancer Research Institute.

The research will focus on furthering the development of CHM 2101 with preclinical studies in gastrointestinal cancers, enhancing the understanding of CHM 2101 through correlative studies and investigating CDH17 directed follow on candidates.

As part of the agreement, Chimeric has the first right of negotiation to license Penn intellectual property arising from the conduct of the sponsored research.

"We are pleased to announce this research agreement as it reflects our shared commitment to the further research and development of CHM 2101 with Dr. Hua and the University of Pennsylvania," said Jennifer Chow, Chief Executive Officer of Chimeric Therapeutics. "We are also thrilled with the progress we have made on driving this important therapy to clinic and are excited as the execution of this agreement will enhance our ability to move forward with that goal."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.



To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

## CONTACT

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)